Phase I study of bevacizumab and sorafenib combined with low dose cyclophosphamide in patients with refractory solid tumors and leukemia.

Trial Profile

Phase I study of bevacizumab and sorafenib combined with low dose cyclophosphamide in patients with refractory solid tumors and leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Sorafenib (Primary)
  • Indications Leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2016 Results from an expansion part of this trial (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 09 Sep 2013 Planned end date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 09 Jan 2012 Planned end date changed from 1 Nov 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top